CalciMedica, Inc.
Business
CalciMedica is a clinical-stage biopharmaceutical company developing small-molecule CRAC channel inhibitors for serious inflammatory and immunologic diseases. Its lead candidate, Auxora (zegocractin), is an intravenously formulated CRAC channel inhibitor in Phase 2 development for acute pancreatitis, acute kidney injury with respiratory failure, and asparaginase-induced pancreatic toxicity, with preclinical and early clinical evidence of efficacy. The company also advances CM5480 for pulmonary arterial hypertension and pursues preclinical research in chronic inflammatory diseases. CalciMedica operates globally with development activities in the United States and international markets.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 15 | 14 | 16 | 8 | 19 | |
| General and administrative | 8 | 10 | 22 | 6 | 17 | |
| Total operating expenses | 23 | 24 | 38 | 14 | 36 | |
| Loss from operations | −23 | −24 | −38 | −14 | −36 | |
| Change in fair value of financial instruments | −6 | 9 | 3 | — | — | |
| Interest expense | −1 | 0 | — | — | — | |
| Interest income | 713,000 | 1 | — | — | — | |
| Other income | 268,000 | 0 | 550,000 | −28,000 | — | |
| Total other income (expense) | −6 | 11 | 4 | 6 | — | |
| Net loss | −30 | −14 | −34 | −8 | −36 | |
| Net loss per share - basic | −1.97 | −1.22 | −7.66 | −111.16 | −1.69 | |
| Net loss per share - diluted | −1.97 | −1.22 | −7.66 | −111.16 | −1.69 | |
| Weighted-average number of shares outstanding used in computing net loss per share - basic | 15 | 11 | 4 | 82,245 | 21 | |
| Weighted-average number of shares outstanding used in computing net loss per share - diluted | 15 | 11 | 4 | 82,245 | 21 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 8 | 6 | 1 | 13 | |
| Short-term investments | 1 | 11 | 6 | 0 | 50 | |
| Prepaid clinical trial expenses | 201,000 | 748,000 | 71,000 | — | — | |
| Other prepaid expenses and current assets | 259,000 | 248,000 | 296,000 | 254,000 | 3 | |
| Assets held for sale | 54,000 | 0 | — | — | — | |
| Total current assets | 14 | 20 | 12 | 2 | 67 | |
| Property and equipment, net | 50,000 | 119,000 | 167,000 | 147,000 | 2 | |
| Other assets | 11,000 | 10,000 | 413,000 | 1 | — | |
| Total assets | 14 | 20 | 12 | 3 | 69 | |
| Accounts payable | 1 | 2 | 1 | 3 | 527,000 | |
| Accrued clinical trial costs | 1 | 820,000 | 1 | 1 | — | |
| Accrued expenses | 290,000 | 866,000 | 1 | 572,000 | — | |
| Current portion, promissory note | 1 | 0 | — | — | — | |
| Total current liabilities | 4 | 4 | 4 | 5 | 4 | |
| Promissory note | 8 | 0 | — | — | — | |
| Warrant liability | 8 | 2 | 0 | 3 | — | |
| Total liabilities | 20 | 5 | 4 | 13 | 4 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | — | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 15,437,410 and 13,481,917, issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 4,000 | 4,000 | 1,000 | 1,000 | 2,000 | |
| Additional paid-in capital | 183 | 174 | 154 | 40 | 234 | |
| Accumulated deficit | −189 | −160 | −146 | −112 | −169 | |
| Accumulated other comprehensive income | 0 | 4,000 | 2,000 | −37,000 | −16,000 | |
| Total stockholders' equity (deficit) | −7 | 14 | 8 | −71 | −64 | |
| Total liabilities and stockholders' equity (deficit) | 14 | 20 | 12 | 3 | 69 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −30 | −14 | −34 | −8 | −36 | |
| Stock-based compensation expense | 3 | 2 | 12 | 2 | 5 | |
| Depreciation | 46,000 | 58,000 | 58,000 | 300,000 | 500,000 | |
| Change in the fair value of warrant liability | 5 | −9 | −1 | −4 | — | |
| Change in the fair value of promissory note | 777,000 | 0 | — | — | — | |
| Promissory note issuance costs | 336,000 | 0 | — | — | — | |
| Transaction costs associated with warrants | 0 | 776,000 | 0 | — | — | |
| Accretion of discount on short-term investments | −345,000 | −608,000 | −145,000 | −319,000 | 58,000 | |
| Change in unrealized losses on investments | −1,000 | 0 | — | — | — | |
| Prepaid expenses, other current and non-current assets | 536,000 | −228,000 | 3 | −2 | 1 | |
| Accounts payable | −840,000 | 601,000 | −1 | 933,000 | −2 | |
| Accrued expenses and other liabilities | −319,000 | −868,000 | −2 | 1 | — | |
| Net cash used in operating activities | −21 | −21 | −26 | −12 | −32 | |
| Purchase of investments | −16 | −29 | −6 | −36 | −95 | |
| Maturity of investments | 25 | 25 | 15 | 64 | 106 | |
| Purchases of property and equipment | −28,000 | −8,000 | −78,000 | −4,000 | −488,000 | |
| Net cash provided by (used in) investing activities | 10 | −4 | 9 | −4,000 | 11 | |
| Proceeds from issuance of common stock, net of issuance costs | 8,000 | 28 | 10 | — | — | |
| Proceeds from exercise of stock options | 25,000 | 20,000 | 0 | — | 695,000 | |
| Proceeds from issuance of promissory note, net | 10 | 0 | — | — | — | |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | 6 | 49,000 | 246,000 | 18,000 | — | |
| Net cash provided by financing activities | 15 | 28 | 21 | 8 | 695,000 | |
| Net increase in cash and cash equivalents | 4 | 2 | 4 | −3 | −20 | |
| Cash paid for interest | 1 | 0 | — | — | — | |
| Financing costs included in accounts payable and accrued expenses | 3,000 | 78,000 | 45,000 | — | — | |
| Equipment purchases included in accounts payable | 3,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CalciMedica, Inc.'s CIK number?
CalciMedica, Inc.'s SEC CIK number is 0001534133 (1534133). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CalciMedica, Inc.'s SEC filings?
All of CalciMedica, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CalciMedica, Inc. last report earnings?
CalciMedica, Inc. (CALC) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218134). This is CalciMedica, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CalciMedica, Inc.'s most recent earnings 8-K?
CalciMedica, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218134. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CalciMedica, Inc.'s latest earnings 8-K →
Look up any company's CIK number →